Altogether, alterations in BRAF gene do not only constitute a valuable diagnosis tool and prognostic factor for some cases of LGG, particularly pilocytic astrocytoma, but also represents an interesting candidate for targeted therapy aimed at reducing the constitutively activated MAPK pathway. Here, BRAF is linked to pilocytic astrocytoma.